Spyre Therapeutics (NASDAQ:SYRE) Sees Unusually-High Trading Volume on Analyst Upgrade

Spyre Therapeutics, Inc. (NASDAQ:SYRE) saw an uptick in trading volume on Wednesday after Robert W. Baird raised their price target on the stock from $65.00 to $90.00. Robert W. Baird currently has an outperform rating on the stock. 632,879 shares changed hands during mid-day trading, a decline of 22% from the previous session’s volume of 816,275 shares.The stock last traded at $65.4410 and had previously closed at $64.01.

Other equities analysts have also recently issued research reports about the company. Leerink Partners lifted their target price on Spyre Therapeutics from $49.00 to $106.00 and gave the company an “outperform” rating in a research note on Monday. Jefferies Financial Group lifted their target price on Spyre Therapeutics from $47.00 to $85.00 and gave the company a “buy” rating in a research note on Monday. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Spyre Therapeutics in a research note on Monday, December 29th. Mizuho raised Spyre Therapeutics to a “strong-buy” rating in a research note on Thursday, December 18th. Finally, Raymond James Financial started coverage on shares of Spyre Therapeutics in a report on Monday. They set a “strong-buy” rating and a $80.00 price target on the stock. Two analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus target price of $82.50.

Insider Activity at Spyre Therapeutics

In related news, CEO Cameron Turtle sold 15,000 shares of the business’s stock in a transaction that occurred on Wednesday, April 1st. The stock was sold at an average price of $49.33, for a total value of $739,950.00. Following the completion of the sale, the chief executive officer owned 627,540 shares of the company’s stock, valued at approximately $30,956,548.20. The trade was a 2.33% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Sheldon Sloan sold 7,958 shares of the business’s stock in a transaction that occurred on Wednesday, April 1st. The shares were sold at an average price of $50.00, for a total value of $397,900.00. Following the completion of the sale, the insider directly owned 7,958 shares of the company’s stock, valued at approximately $397,900. The trade was a 50.00% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 62,958 shares of company stock valued at $2,734,375. 15.43% of the stock is owned by corporate insiders.

More Spyre Therapeutics News

Here are the key news stories impacting Spyre Therapeutics this week:

• Positive Sentiment: Mid‑stage clinical data for SPY001 showed reduced disease activity and strong efficacy signals in ulcerative colitis (rapid, deep responses and a clean safety profile), giving the program potential “best‑in‑class” upside and a clear near‑term clinical catalyst. Article Title
• Positive Sentiment: Multiple bullish analyst notes and price‑target increases — including a Raymond James initiation with a strong‑buy stance and several firms raising targets (e.g., Baird raised its target to $90) — are supporting upside expectations and likely amplifying buying interest. Article Title
• Positive Sentiment: Independent research houses (BTIG, Leerink Partners and others) published bullish forecasts and price‑target lifts, reinforcing conviction among institutional investors and contributing to momentum. Article Title
• Neutral Sentiment: Spyre priced an upsized public offering of 6.5M shares at $62.00/share to raise roughly $403M (with a 30‑day option for additional shares). This materially improves cash runway for development programs but is dilutive and could weigh on the share count/near‑term EPS. Closing expected around April 16, subject to customary conditions. Article Title
• Negative Sentiment: Significant insider selling has been reported over recent months (multiple sales by executives), a flag some investors watch closely for signaling. Heavy insider sales can amplify concern about timing/valuation despite positive news flow. Article Title
• Negative Sentiment: Earlier coverage highlighted an initial negative reaction to plans for a stock offering (shares had fallen on offering news), underscoring how dilution risk can offset clinical and analyst positives. Article Title

Institutional Investors Weigh In On Spyre Therapeutics

Several large investors have recently made changes to their positions in the company. Optimize Financial Inc boosted its holdings in Spyre Therapeutics by 1.5% in the fourth quarter. Optimize Financial Inc now owns 25,331 shares of the company’s stock worth $830,000 after purchasing an additional 364 shares in the last quarter. Mercer Global Advisors Inc. ADV boosted its holdings in Spyre Therapeutics by 0.5% in the third quarter. Mercer Global Advisors Inc. ADV now owns 106,664 shares of the company’s stock worth $1,788,000 after purchasing an additional 522 shares in the last quarter. California State Teachers Retirement System boosted its holdings in Spyre Therapeutics by 1.8% in the second quarter. California State Teachers Retirement System now owns 33,201 shares of the company’s stock worth $497,000 after purchasing an additional 603 shares in the last quarter. AQR Capital Management LLC boosted its holdings in Spyre Therapeutics by 4.5% in the fourth quarter. AQR Capital Management LLC now owns 17,820 shares of the company’s stock worth $584,000 after purchasing an additional 773 shares in the last quarter. Finally, Universal Beteiligungs und Servicegesellschaft mbH boosted its holdings in Spyre Therapeutics by 1.1% in the third quarter. Universal Beteiligungs und Servicegesellschaft mbH now owns 110,456 shares of the company’s stock worth $1,851,000 after purchasing an additional 1,172 shares in the last quarter. Institutional investors own 80.39% of the company’s stock.

Spyre Therapeutics Price Performance

The stock has a market capitalization of $5.44 billion, a P/E ratio of -33.17 and a beta of 2.93. The stock’s fifty day moving average is $43.78 and its 200-day moving average is $33.33.

Spyre Therapeutics (NASDAQ:SYRE) last announced its earnings results on Thursday, February 19th. The company reported ($0.70) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.66) by ($0.04). On average, research analysts expect that Spyre Therapeutics, Inc. will post -4.46 EPS for the current year.

About Spyre Therapeutics

Spyre Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel immunotherapies for cancer. The company leverages proprietary protein engineering and biologics design platforms to create targeted molecules intended to enhance anti-tumor immune responses and inhibit tumor growth. Its preclinical pipeline comprises multiple candidate therapies for solid tumor and hematologic oncology indications.

Established by a team with deep expertise in protein design, immunology and translational research, Spyre Therapeutics collaborates with leading academic institutions and research organizations to accelerate its discovery efforts.